These findings suggest that β‐AR activation and phosphodiesterase 4 (PDE4) inhibition mitigate oAβ‐induced memory deficits, supporting enhanced cAMP signaling as a therapeutic target for early AD. Here, PDE4A is linked to Alzheimer disease.